Device Trial Radar · NCT05823090
Light Therapy for Depression in Adolescent Outpatients
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Dec 21, 2021
Primary completion
Nov 8, 2022
Study completion Nov 8, 2022
Sponsor
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years, up to 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this placebo lead-in clinical trial was to test bright light therapy (BLT) in adolescents with depression. The main question\[s\] it aimed to answer were: 1. characterize and define facilitators/barriers to treatment with BLT in adolescents); 2. evaluate the acceptability and feasibility of outpatient BLT in a dose titration protocol; 3. establish an effective, safe and tolerable light dose.
Conditions
- Depression
- Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)Device
The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Depression SeverityTime frame: Baseline to week 2, week 8
- Adherence to BLT in Adolescent Outpatients With DepressionTime frame: 8 week study period (measured at Week 2, Week 4, and Week 8)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Rachel Ballard
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.